FOR ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CD
*In both the CD and UC studies, many patients achieved clinical remission at 1 year with STELARA®.
6-WEEK RAPID RESPONSE:
Many patients achieved clinical response† at Week 6 and 70-point response as early as Week 3 in clinical studies1
Many patients achieved clinical remission‡ at 1 year in a clinical study1
STELARA® has a proven safety profile through 1 year. Plus safety data through 5 years (from Phase 3 studies and open-label LTE)1,2
CD=Crohn's disease; CDAI=Crohn's Disease Activity Index; LTE=long-term extension; UC=ulcerative colitis.
†Clinical response was defined as reduction in CDAI score of ≥100 points or CDAI score of <150.
‡Clinical remission was defined as a CDAI score of <150.
References: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc.